Karyopharm Initiates Registration-Directed Clinical Study of Selinexor (KPT-330) in Patients With Richter's Transformation
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/11/2026
- Wall Street ends higher as investors turn to earnings season
- Oil prices settle lower on hopes for smoother shipping in Strait of Hormuz
- The real reason Meta shares are surging has nothing to do with its new AI model
- Stifel lifts Shopify to Buy, sees agentic commerce as next growth catalyst
- Delta Air Lines stock climbs on earnings beat and strong guidance
- Almonty Industries (ALM) PT Raised to $33 at DA Davidson
- JPMorgan analysts name top short ideas for third quarter 2026
- The real reason Meta shares are surging has nothing to do with its new AI model
- Wall Street ends higher as investors turn to earnings season
- AppLovin gains market share among e-commerce advertisers
Karyopharm Therapeutics (KPTI) Initiates Selinexor Phase 2 in SIRRT Patients
November 10, 2014 7:22 AM ESTKaryopharm Therapeutics (Nasdaq: KPTI) announced the initiation of its Phase 2 study of Selinexor (KPT-330) in patients with Richter's transformation (SIRRT) that is relapsed after or refractory to chemotherapy. This multi-center study of Selinexor, one of the company's novel, oral Selective Inhibitor of Nuclear Export / SINE compounds, will enroll approximately 50 patients in approximately 35 sites worldwide.
This single arm, open-label, Phase 2 study will... More
Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 9c
November 10, 2014 7:21 AM ESTKaryopharm Therapeutics (NASDAQ: KPTI) reported Q3 EPS of ($0.61), $0.09 worse than the analyst estimate of ($0.52).
For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.
... More